Showing results (611-620 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|July 16, 2024
Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting systemRuiqi Zhao, Mengyao Han, Sen Lin, et al.Expert Opinion on Drug Safety|July 4, 2024
Analysis of hemorrhagic drug-drug interactions between P-gp inhibitors and direct oral anticoagulants from the FDA Adverse Event Reporting SystemMengyao Li, Jian Xiao, Ting Yu, et al.Expert Opinion on Drug Safety|April 11, 2024
Antibiotics-associated pseudomembranous colitis: a disproportionality analysis of the US food and drug administration adverse event reporting system (FAERS) databaseJinhua Chen, Weijiang Yu, Wancun Zhang, et al.Expert Opinion on Drug Safety|September 3, 2024
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literatureCarlos De Las Cuevas, Victoria C de Leon, Hilario Blasco-Fontecilla, et al.Expert Opinion on Drug Safety|September 5, 2024
A real-world disproportionality analysis of baloxavir marboxil: post-marketing pharmacovigilance dataJie Zhou, Junchang Ye, Maohua Chen, et al.Expert Opinion on Drug Safety|September 12, 2024
Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting systemWenjie Li, Ruxue Lv, Wei WangExpert Opinion on Drug Safety|September 14, 2024
Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024Fuchun Zheng, Fei Wang, Yuyang Yuan, et al.Expert Opinion on Drug Safety|September 30, 2024
The safety of available pharmacotherapy for stroke prevention in atrial fibrillationG Denas, G Santostasi, V PengoExpert Opinion on Drug Safety|September 16, 2024
From common to unreported: a real-world study of adverse events to duloxetine in the treatment of osteoarthritisJingkai Di, Likun Qi, Lujia Liu, et al.Expert Opinion on Drug Safety|October 23, 2024
Real-world analysis of levetiracetam-associated rhabdomyolysis: insights from the FDA adverse event reporting systemGuo Yinan, Gong Guangming, Guo Guangyu, et al.Pageof 282